HYUNDAI BIOSCIENCE CO., LTD. Logo

HYUNDAI BIOSCIENCE CO., LTD.

Develops antiviral and anticancer drugs using a proprietary drug delivery system.

048410 | KO

Overview

Corporate Details

ISIN(s):
KR7048410005
LEI:
Country:
South Korea
Address:
경상북도 김천시 아포읍 아포공단길 106, 김천시

Description

HYUNDAI BIOSCIENCE CO., LTD. is a biotechnology company focused on developing innovative therapeutics using its proprietary drug delivery system (DDS) technology. The company's core science is based on organic-inorganic hybrid technologies designed to safely and effectively deliver active ingredients. Its main development pipeline includes CP-COV03, a broad-spectrum antiviral agent that enhances cellular autophagy to combat viral infections, and Polytaxel, an anticancer drug candidate developed with polymer transfer technologies to reduce toxicity. The company's primary focus is on creating novel treatments for viral diseases and cancer.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2023-10-05 00:00
주주총회소집결의(임시주주총회)
Korean 6.3 KB
2023-10-05 00:00
주주명부폐쇄기간또는기준일설정
Korean 4.5 KB
2023-08-11 00:00
반기보고서 (2023.06)
Korean 1.1 MB
2023-07-25 00:00
주식매수선택권부여에관한신고
Korean 20.3 KB
2023-07-04 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 23.7 KB
2023-05-15 00:00
분기보고서 (2023.03)
Korean 965.7 KB
2023-04-28 00:00
투자판단관련주요경영사항(코로나바이러스감염증-19 치료제 CP-COV03의 제2상 임상시험 결과)
Korean 21.2 KB
2023-04-13 00:00
[기재정정]투자판단관련주요경영사항(코로나바이러스감염증-19 치료제 CP-COV03의 제2상 임상시험 통계분석 결과 발표)
Korean 41.1 KB
2023-04-10 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 22.9 KB
2023-03-28 00:00
정기주주총회결과
Korean 21.3 KB
2023-03-28 00:00
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 11.7 KB
2023-03-20 00:00
사업보고서 (2022.12)
Korean 1.3 MB
2023-03-17 00:00
감사보고서제출
Korean 24.3 KB
2023-03-13 00:00
주주총회소집결의
Korean 9.8 KB
2023-03-13 00:00
주주총회소집공고
Korean 100.3 KB

Automate Your Workflow. Get a real-time feed of all HYUNDAI BIOSCIENCE CO., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for HYUNDAI BIOSCIENCE CO., LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for HYUNDAI BIOSCIENCE CO., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

1NKEMIA Logo
Biotechnology company providing R&D and services for the life sciences sector.
Spain
IKM
2cureX AB Logo
Develops an IVD test using 3D tumoroids to predict patient response to cancer drugs.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation company developing biologic medicines.
United States of America
ABSI
Achiko AG Logo
A digital services platform for cross-border business compliance and engagement.
Switzerland
ACHI
Active Biotech Logo
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
Sweden
ACTI
Adagene Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for oncology.
United States of America
ADAG

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.